Key result
Heterozygous status of HOPX gene In/Del and C/T polymorphisms was significantly associated with syncope in hypertrophic cardiomyopathy patients, while homozygous status was protective.
Why the study?
Do HOPX gene polymorphisms associate with syncope in patients with hypertrophic cardiomyopathy?
Case-Control (n=98)
Do HOPX gene polymorphisms associate with syncope in patients with hypertrophic cardiomyopathy?
p-value: p=0.014
Heterozygous non-coding polymorphisms in the HOPX gene are associated with an increased risk of syncope in patients with hypertrophic cardiomyopathy, suggesting a potential role as a genetic modifier.
HOPX variants may flag syncope risk in HCM; hypothesis-generating for genetic modifiers and requires prospective validation before clinical use.
OBJECTIVE: Homeodomain Only Protein X (HOPX) is an unusual homeodomain protein which regulates Serum Response Factor (SRF) dependent gene expression. Due to the regulatory role of HOPX on SRF activity and the regulatory role of SRF on cardiac hypertrophy, we aimed to investigate the relationship between HOPX gene variations and hypertrophic cardiomyopathy (HCM). METHODS: In this study, designed as a case-control study, we analyzed coding and flanking non-coding regions of the HOPX gene through 67 patients with HCM and 31 healty subjects. Certain regions of the gene were investigated by Single Stranded Conformation Polymorphism (SSCP) and Restriction Fragment Length Polymorphism (RFLP). Statistical analyses of genotypes and their relationship with clinical parameters were performed by chi-square, Kruskal-Wallis and the Fisher's exact test. RESULTS: In 5' Untranslated Region (UTR) and intronic region of the HOPX gene, we found a C>T substitution and an 8-bp insertion/deletion (In/Del) polymorphism, respectively. These two polymorphisms seemed to constitute an haplotype. While the frequency of homozygous genotypes of In/Del and C/T polymorphisms were found significantly lower in the patients with syncope (p=0.014 and p=0.017, respectively), frequency of their heterozygous genotypes were found significantly higher in the patients with syncope (p=0.048 and p=0.030, respectively). CONCLUSİON: Though there was not found any mutation in coding sequence of HOPX gene, two non-coding polymorphisms were found related to syncope in HCM patients. While homozygous status of these polymorphisms was found to be protective against the syncope, their heterozygous status seemed to be a risk factor for syncope in HCM patients. Our results suggest that HOPX may contribute to pathogenesis or manifestation of HCM as a modifier gene.
No takes yet. Share an insight, caveat, or question.
Güleç et al. (2014) conducted a case-control in Hypertrophic cardiomyopathy (n=98). HOPX gene non-coding polymorphisms (C>T substitution and 8-bp In/Del) vs. Homozygous genotypes / Healthy controls was evaluated on Syncope in HCM patients (p=0.014). Heterozygous status of HOPX gene In/Del and C/T polymorphisms was significantly associated with syncope in hypertrophic cardiomyopathy patients, while homozygous status was protective.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: